Newron Pharmaceuticals Statistics

Total Valuation

FRA:NP5 has a market cap or net worth of EUR 389.51 million. The enterprise value is 398.85 million.

Market Cap	389.51M
Enterprise Value	398.85M

Important Dates

The next estimated earnings date is Thursday, December 18, 2025.

Earnings Date	Dec 18, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	19.96M
Shares Outstanding	n/a
Shares Change (YoY)	+16.86%
Shares Change (QoQ)	-11.63%
Owned by Insiders (%)	4.81%
Owned by Institutions (%)	6.34%
Float	19.00M

Valuation Ratios

The trailing PE ratio is 15.38.

PE Ratio	15.38
Forward PE	n/a
PS Ratio	6.50
PB Ratio	246.21
P/TBV Ratio	246.37
P/FCF Ratio	15.88
P/OCF Ratio	15.86
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.31, with an EV/FCF ratio of 16.26.

EV / Earnings	15.75
EV / Sales	6.68
EV / EBITDA	11.31
EV / EBIT	11.36
EV / FCF	16.26

Financial Position

The company has a current ratio of 1.51, with a Debt / Equity ratio of 33.23.

Current Ratio	1.51
Quick Ratio	1.40
Debt / Equity	33.23
Debt / EBITDA	1.49
Debt / FCF	2.14
Interest Coverage	8.00

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	50.97%
Return on Invested Capital (ROIC)	60.97%
Return on Capital Employed (ROCE)	165.16%
Revenue Per Employee	2.72M
Profits Per Employee	1.15M
Employee Count	22
Asset Turnover	1.39
Inventory Turnover	n/a

Taxes

In the past 12 months, FRA:NP5 has paid 5.55 million in taxes.

Income Tax	5.55M
Effective Tax Rate	17.99%

Stock Price Statistics

The stock price has increased by +152.55% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+152.55%
50-Day Moving Average	15.86
200-Day Moving Average	10.08
Relative Strength Index (RSI)	62.47
Average Volume (20 Days)	1,662

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:NP5 had revenue of EUR 59.88 million and earned 25.33 million in profits. Earnings per share was 1.19.

Revenue	59.88M
Gross Profit	59.88M
Operating Income	35.20M
Pretax Income	30.88M
Net Income	25.33M
EBITDA	35.21M
EBIT	35.20M
Earnings Per Share (EPS)	1.19

Full Income Statement

Balance Sheet

The company has 43.20 million in cash and 52.57 million in debt, giving a net cash position of -9.37 million.

Cash & Cash Equivalents	43.20M
Total Debt	52.57M
Net Cash	-9.37M
Net Cash Per Share	n/a
Equity (Book Value)	1.58M
Book Value Per Share	0.08
Working Capital	20.39M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 24.57 million and capital expenditures -37,000, giving a free cash flow of 24.53 million.

Operating Cash Flow	24.57M
Capital Expenditures	-37,000
Free Cash Flow	24.53M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of 58.78% and 42.30%.

Gross Margin	100.00%
Operating Margin	58.78%
Pretax Margin	51.57%
Profit Margin	42.30%
EBITDA Margin	58.81%
EBIT Margin	58.78%
FCF Margin	40.96%

Dividends & Yields

FRA:NP5 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.86%
Shareholder Yield	-16.86%
Earnings Yield	6.50%
FCF Yield	6.30%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:NP5 has an Altman Z-Score of 4.83 and a Piotroski F-Score of 5.

Altman Z-Score	4.83
Piotroski F-Score	5